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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 
102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and 




EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via 
the Competent Authority of France, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to 
deliver an opinion on the scientific substantiation of a health claim related to a combination of Bifidobacterium 
longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus 
LA 104 and reducing intestinal discomfort. The food that is the subject of the health claim is a combination of 
four bacterial strains—B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104. 
The Panel considers that the food, a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 
and S. thermophilus LA 104, which is the subject of the health claim is sufficiently characterised. The claimed 
effect proposed by the applicant is ―improves intestinal comfort‖. The Panel considers that reduction of gastro-
intestinal discomfort is a beneficial physiological effect. The Panel considers that the only human study provided 
for the substantiation of the claim (with limitations) did not find an effect of a combination of the bacterial 
strains being the subject of the claim on gastrointestinal discomfort. The Panel concludes that a cause and effect 
relationship has not been established between the consumption of a combination of B. longum LA 101, 
L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and reducing gastro-intestinal discomfort. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 
1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, 
Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal 
discomfort. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data. 
The food that is the subject of the health claim is a combination of B. longum LA 101, L. helveticus 
LA 102, L. lactis LA 103 and S. thermophilus LA 104. The Panel considers that the food, a 
combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 
104, is sufficiently characterised. 
The claimed effect proposed by the applicant is ―improves intestinal comfort‖. The target population 
proposed by the applicant is people characterised by a digestive discomfort such as bloating and 
flatulence and change in stool frequency. The Panel considers that reduction of gastro-intestinal 
discomfort is a beneficial physiological effect. 
For the scientific substantiation of the claim, the applicant provided the results of one published 
human study and one in vitro study. The Panel considers that the only human study provided (with 
methodological limitations) did not find an effect of a combination of the bacterial strains being the 
subject of the claim on reducing gastrointestinal discomfort. The Panel considers that the in vitro study 
evaluating survival of the four bacterial strains that are the subject of the claim in an artificial gastro-
intestinal model does not provide data that can be used for the substantiation of a claim related to 
gastro-intestinal discomfort. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of B. longum LA 101, L. helveticus LA 
102, L. lactis LA 103 and S. thermophilus LA 104 and reducing intestinal discomfort. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 11/11/2013. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 The scientific evaluation procedure started on 4/12/2013. 
 On 22/01/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 29/01/2014 and restarted on 05/02/2014, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
 On 05/02/2014, EFSA received the requested information (which was made available to EFSA 
in electronic format on 04/02/2014). 
 During its meeting on 10/04/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a combination 
of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and 
reducing intestinal discomfort. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to a combination of B. longum LA 101, L. 
helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 and reducing intestinal discomfort. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of a combination of B. longum LA 101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus 
LA 104, a positive assessment of its safety, nor a decision on whether a combination of B. longum LA 
101, L. helveticus LA 102, L. lactis LA 103 and S. thermophilus LA 104 is, or is not, classified as a 
foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation 
(EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: PiLeJe, 37 Quai de Grenelle, 75738 Paris Cedex 15, France. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 (Drouault-Holowacz et al., 2008). 
Food/constituent as stated by the applicant 
According to the applicant, the food for which a health claim is made is a combination of four 
bacterial strains—Bifidobacterium longum LA 101 (29 %), Lactobacillus helveticus LA 102 (29 %), 
Lactococcus lactis LA 103 (29 %) and Streptococcus thermophilus LA 104 (13 %)—mixed with 
excipients as mentioned below: potato starch (Perfectamyl D6) (quantity per 2.5 g sachet—1.956 g), 
dextrose (ROFEROSE® ST) (0.25 g), maltodextrin (GLUCIDEX®) (0.03 g), chicory fructo-
oligosaccharides (Beneo®P95), mix of four probiotic strains (0.114 g) and cellulose (Avicell® PH) 
(0.025 g). 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is ―improves intestinal comfort‖. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: ―improves intestinal comfort‖, 
―helps to alleviate/decrease intestinal discomfort‖, ―helps to alleviate/reduces bloating‖ and ―helps to 
alleviate/reduces flatulence‖. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of one sachet (2.5 g) per day for 28 days. Each sachet has to be 
taken once daily in the fasting state, at least 3 hours after a meal and 15 minutes before the next meal. 
The powder has to be dissolved in water 10 minutes before its ingestion. The target population is 
people characterised by a digestive discomfort such as bloating and flatulence and change in stool 
frequency. 
ASSESSMENT 
1. Characterisation of the food 
The food that is the subject of the health claim is a combination of four bacterial strains—
Bifidobacterium longum LA 101 (29 %), Lactobacillus helveticus LA 102 (29 %), Lactococcus lactis 
LA 103 (29 %) and Streptococcus thermophilus LA 104 (13 %)—with other food ingredients or 
excipients: 1.96 g potato starch (Perfectamyl D6), 0.25 g dextrose (ROFEROSE® ST), 0.03 g 
maltodextrin (GLUCIDEX®), 0.125 g chicory fructo-oligosaccharides (Beneo®P95) and 0.025 g 
cellulose (Avicell® PH). The concentration of the bacterial strains in colony-forming units (CFU) is 
10
10
 CFU per sachet (2.9  10
9
 CFU B. longum LA 101; 2.9  10
9
 CFU L. helveticus LA 102; 
2.9  10
9
 CFU L. lactis LA 103; 1.3  10
9
 CFU S. thermophilus LA 104). 
Data related to microbiological safety and stability of the strains were provided. 
The strain B. longum LA 101 (also named R0175) was deposited in the Collection Nationale de 
Cultures de Microorganismes (CNCM) under the deposit number I-3470. The CNCM is a restricted-
access non-public collection which has the status of International Depositary Authority under the 
Budapest Treaty. Data on phenotypic (morphology, fermentation pattern, biochemical tests) and 
genotypic characterisation of the strain, including species-specific polymerase chain reaction (PCR) 
and 16S rRNA gene and tuf gene sequence analyses for species identification, and pulsed-field gel 
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electrophoresis (PFGE) for strain typing, were provided. The Panel considers that the strain B. longum 
LA 101 is sufficiently characterised. 
The strain L. helveticus LA 102 (also named R0052) was deposited in the CNCM under the deposit 
number I-1722. Data on phenotypic (morphology, fermentation pattern, enzymatic activities, 2D-
protein analysis) and genotypic characterisation of the strain, including 16S rRNA gene and 16S–23S 
rRNA intergenic region sequence analyses, DNA–DNA hybridisation and amplified ribosomal DNA 
restriction analysis (ARDRA) for species identification, and PFGE for strain typing, were provided. 
According to the applicant, this strain was initially identified as L. acidophilus, but more recently re-
classified as L. helveticus. The Panel considers that the strain L. helveticus LA 102 is sufficiently 
characterised. 
The strain L. lactis LA 103 (also named R1058) was deposited in the CNCM under the deposit number 
MA 67/4J. Data on phenotypic (morphology, fermentation pattern, biochemical tests) and genotypic 
characterisation of the strain, including 16S rRNA gene sequence analysis for species identification 
and multi-locus sequence typing (MLST), randomly amplified polymorphic DNA (RAPD) and PFGE 
analyses for strain typing, were provided. The Panel considers that the strain L. lactis LA 103 is 
sufficiently characterised. 
The strain S. thermophilus LA 104 (also named R1018) was characterised phenotypically 
(morphology, fermentation pattern, biochemical tests) and genotypically, including 16S rRNA gene 
sequence analysis for species identification and PFGE for strain typing. The strain was deposited in 
the CNCM with the number CNCM-I4691. The Panel considers that the strain S. thermophilus LA 104 
is sufficiently characterised. 
The Panel considers that the food, a combination of B. longum LA 101, L. helveticus LA 102, L. lactis 
LA 103 and S. thermophilus LA 104, which is the subject of the health claim is sufficiently 
characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is ―improves intestinal comfort‖. The target population 
proposed by the applicant is people characterised by a digestive discomfort such as bloating and 
flatulence and change in stool frequency. 
The Panel considers that reduction of gastrointestinal discomfort is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in the PubMed database. The following search terms were 
used: ―probiotic‖, ―probiotics‖, ―Lactibiane‖, ―probiotic/ibs‖, ―probiotics/ibs‖, ―probiotic/transit‖, 
―probiotics/transit‖. A manual search was also performed. 
The applicant identified one published human study (Drouault-Holowacz et al., 2008, claimed as 
proprietary) and one in vitro study (Denis et al., unpublished) as pertinent to the claim. 
A placebo-controlled, randomised, double-blind, multi-centre, parallel study by Drouault-Holowacz et 
al. (2008) investigated the effects of daily consumption of the combination of bacterial strains which is 
the subject of the claim on symptoms related to gastro-intestinal discomfort. The study was performed 
in a group of 116 outpatients with irritable bowel syndrome (IBS) according to the Rome II criteria 
and a discomfort/pain score superior or equal to 1 assessed using a 0–3 Likert scale. The combination 
of four bacterial strains which is the subject of the claim, was provided in the form of 2.5 g sachet 
taken once daily or placebo (of identical appearance and identical composition except for the bacterial 
strains) and was given randomly for four weeks. A questionnaire assessing intensity of symptoms was 
completed by the subjects each week. The primary outcome was ―satisfactory relief‖ of overall IBS 
symptoms measured weekly by a binary scale answer (Yes/No) to a question about satisfactory relief 
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of IBS symptoms as reported in a previous study (Kellow et al., 2003). The subjects also had to 
answer a second question related to the relief of symptoms of abdominal discomfort/pain using a scale 
with five different severity descriptors in accordance with Müller-Lissner et al. (2001). It was unclear 
to the Panel whether answers to both questions were used to determine the primary outcome (and how 
results were combined) or if the second question was used only to determine the secondary outcome 
(abdominal pain). Upon a  request by EFSA, the applicant indicated that both questions were used for 
the assessment of the primary outcome, defined as ―satisfactory relief‖ of overall IBS symptoms, and 
that relief of pain was treated as a secondary outcome. Other secondary endpoints included weekly 
assessment of discomfort/pain, intensity of abdominal pain using a 10 cm visual analogue scale (0, not 
at all; 10, acute, unimaginable) and self-assessment of stool frequency and consistency. Additionally, 
subjects completed the IBS specific FDD-QoL (Functional Digestive Disorders Quality-of-Life) 
questionnaire and health status Short Form-36 (SF-36) questionnaire at baseline and at the end of the 
treatment. 
The study was adequately powered in relation to primary outcomes. A total of 100 subjects finished 
the study (76 women, mean age 46 years, 48 in the study group and 52 in control group). The reasons 
for drop-outs (one in the placebo group and five in the test group) were given. Characteristics of 
subjects of both groups were reported to be comparable at baseline regarding discomfort/pain score. 
In statistical analysis of the results, the differences in items from questionnaires between the two 
intervention groups were analysed applying the two-sided chi
2
-test or Fisher exact test, as appropriate. 
Answers on visual analogue scales were measured in centimetres and compared (row values and 
changes expressed in percentages) between groups by the Mann–Whitney test and within groups 
(week 5 and week 1) by Wilcoxon’s rank-sum test. The percentage of variation were calculated using 
the formula ([Wk4 –Wk0]/Wk0)  100. The Panel notes that correction for multiple comparisons was 
not taken into account in the statistical analyses. In the study report, the results were presented as  both 
per protocol (PP) (100 subjects) and intention to treat (ITT) (106 subjects) analyses. 
The study reported that the combination of bacterial strains had no effect on the primary outcome, 
―relieving symptoms of IBS‖, compared with placebo (42.6 % of subjects with improvement vs. 42.3 
% subjects with improvement in per protocol analysis, and 37.7 % vs. 42.7 % in ITT analysis). The 
differences in relation to relief of symptoms of abdominal discomfort/pain with the use of five scale 
questionnaires were not statistically significant for each of five time points measured for both PP and 
ITT analyses. The differences in the intensity of pain/discomfort on the visual analogue scale, stool 
frequency and consistency, SF-36 and FDD-QoL were also not statistically significant. Significant 
differences were reported for some components of the questionnaires only and in certain subgroups of 
subjects and were inconsistent at different time points. The Panel notes that results of these secondary 
analyses were inconsistent. 
The Panel notes also that only two of the questionnaires used in the study were validated (SF-36 and 
FDD-QoL), while other questionnaires/scales were previously used in other studies. Upon a request by 
EFSA regarding the validation of questionnaires/scales, the applicant indicated that ―they employed 
definitions of clinically meaningful improvement in IBS as a patient response (yes or not) of 
satisfactory relief of overall IBS symptoms or abdominal pain and discomfort (Irvine et al., 2006) and 
that these definitions are assumed to have faced validation‖. The Panel notes that the previous use of a 
questionnaire/scale is not necessarily a proof of validity and that the applicant has not provided 
specific evidence of the validation of the questionnaires used. 
The Panel considers that this study (with some methodological limitations) did not show an effect of a 
combination of bacterial strains, which is the subject of the claim, on gastro-intestinal discomfort. 
In the second study provided, the survival of the four bacterial strains, a combination of which is the 
subject of the claim, was evaluated in an artificial gastro-intestinal model (TIM) (Denis et al., 
unpublished). The Panel considers that this study does not provide data that can be used for the 
substantiation of a claim related to gastro-intestinal discomfort. 
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In weighing the evidence, the Panel considers that the only human study (with methodological 
limitations) provided for the substantiation of the claim did not show an effect of a combination of the 
bacterial strains, which is the subject of the claim, on reducing gastro-intestinal discomfort. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, 
Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing gastro-intestinal 
discomfort. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 
102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104, which is the subject 
of the health claim, is sufficiently characterised. 
 The claimed effect is ―improves intestinal comfort‖. The target population proposed by the 
applicant is people characterised by a digestive discomfort such as bloating and flatulence and 
change in stool frequency. The Panel considers that reduction of gastro-intestinal discomfort is 
a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, 
Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing gastro-
intestinal discomfort. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a combination of Bifidobacterium longum LA 101, Lactobacillus 
helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing 
intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 
0401_FR). November 2013. Submitted by PiLeJe. 
REFERENCES 
Denis S, Alric M, Holowacz S, Martin F, Rousseau V and Paul F, unpublished. Collaboration de 
Recherche No ERT 03/01 (suite de la collaboration No ERT02/02, Rapport final). 
Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X and Marteau P, 2008. A double 
blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel 
syndrome. Gastroentérologie Clinique et Biologique, 32, 147–152. 
Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ 
and Design of Treatment Trials Committee, 2006. Design of treatment trials for functional 
gastrointestinal disorders. Gastroenterology, 130, 1538–1551. 
Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J and 
Wagner A, 2003. An Asia-Pacific, double blind, placebo controlled randomised study to evaluate 
the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut, 52, 
671–676. 
Müller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B and Ruegg P, 2001. 
Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome 
patients with abdominal pain, bloating and constipation. Alimentary Pharmacology and 
Therapeutics, 15, 1655–1666. 
A combination of LA101, LA102, LA103 and LA104 and intestinal discomfort  
 
 
10 EFSA Journal 2014;12(5):3658 
ABBREVIATIONS 
ARDRA amplified ribosomal DNA restriction analysis 
CFU colony-forming unit 
CNCM Collection Nationale de Cultures de Microorganismes 
DNA deoxyribonucleic acid 
FDD Functional Digestive Disorders 
IBS irritable bowel syndrome 
ITT intention to treat 
MLST multi-locus sequence typing 
PCR polymerase chain reaction 
PFGE pulsed-field gel electrophoresis 
PP per protocol 
RAPD randomly amplified polymorphic DNA 
RNA ribonucleic acid 
SF-36 Short Form-36 
TIM polyfermentor intestinal model 
 
